Link to the San Antonio Breast Cancer Symposium 2022 poster...

Link to the San Antonio Breast Cancer Symposium 2022 poster

https://static1.squarespace.com/sta...b/1670539377946/21094 SABCS 2022 11-11-22.pdf

Link to the ACCR April 2023 poster

https://static1.squarespace.com/sta...2d/1681895764090/AACR 2023 FINAL 4-6-2023.pdf


The poster presented at the ESMO October 2023 conference in Madrid was not published on the Imugene website. The data readout of results were to December 2022 and were identified in the abstract

487P - Induction of an inflammatory tumor microenvironment with oncolytic virus CF33-hNIS-antiPD-L1 intratumoral injection in patients with metastatic triple-negative breast cancer (mTNBC)

The results for the CHECKvacc Phase 1 Trial in TNBC
From October 2021 to December 2022, 8 patients were enrolled
... received ≥1 dose of CHECKvacc at 1 of the first 3 dose levels (1x105, 3x105, 1x106 PFU).
There were no dose limiting toxicities.
Six patients had evaluable baseline and post-treatment tissues for immune quantification.
From baseline to cycle 1 day 2,
CD8+ T cells in the TME increased in 5 of 6 patients (median increase: 34%; range: 9-251%).
CD4+ T cells increased in 4 of 6 patients (median increase: 39%; range: 23-73%).
PD-L1 expression by CPS increased in 5 of 6 patients (range of increase: 4-50%; p=0.063 by Wilcoxon signed-rank test).

The conclusion reached was
CHECKvacc induces tumor infiltration of CD4+ and CD8+ T cells.
Upregulation of PD-L1 within the tumor microenvironment further suggests immune activation by CHECKvacc.

In the recent Quarterly Activities 4C Cash Flow Report released in October 2023 it was reported

"After completion of the current cohort 4, the data derived from this trial will be used to
inform our other CF33 clinical developments, and resources and finances from this study
will be re directed to our priority programs".

The 2023 San Antonio Breast Cancer Symposium commenced today but unfortunately there does not appear to be any presentation of CHECKvacc results.